The blood and blood components industry is positioned for substantial growth between 2025 and 2032, driven by rising demand for transfusion services and advances in blood processing technologies. This market’s dynamics are influenced by evolving healthcare infrastructure and increased awareness of blood-related therapies globally.
Market Size and Overview
The global Blood and Blood Components Market size is estimated to be valued at USD 40,779 million in 2025 and is expected to reach USD 56,242.3 million by 2032, exhibiting a compound annual growth rate (CAGR) of 4.7% from 2025 to 2032.
The growth forecast reflects Blood and Blood Components Market revenue gains attributed to technological innovations in blood storage and component separation, alongside increased clinical applications. Market trends indicate steady expansion fueled by emergent blood banking technologies and regulatory support worldwide.
Market Segments and Analysis
The market scope can be categorized broadly into product type, end-user, and application segments.
- Product Type: Includes whole blood, red blood cells, platelets, plasma, and cryoprecipitate. Among these, red blood cells remain the dominant sub-segment due to their critical role in treating anemia and surgical blood loss, contributing majorly to market revenue by 2024. Platelets are the fastest-growing sub-segment, propelled by their increased use in oncology and chronic disease management documented in 2025 case studies.
- End User: Hospitals, blood banks, and research institutes. Hospitals serve as the primary revenue driver, with expanding transfusion procedures worldwide, while specialized blood banks exhibit rapid growth, highlighted by regional capacity expansions reported in 2024.
- Application: Surgical procedures, trauma care, chronic disease management, and diagnostic testing. Surgical procedures dominate, but chronic disease management is exhibiting the fastest growth trajectory owing to rising instances of hemophilia and thalassemia patients receiving blood therapies in 2025.
Market Drivers
One key market driver is the advancement in blood component separation technologies, such as automated apheresis systems introduced by multiple market companies in 2024. Increasing adoption of such technologies enhances safety, product quality, and donor-to-recipient compatibility, which was reported to raise blood component availability by approximately 12% in healthcare facilities globally. Regulatory frameworks supporting voluntary blood donation and improved cold chain logistics also contribute substantially to market growth strategies.
Segment Analysis: Product Type
Focusing on the product type segment, red blood cells accounted for the highest revenue in 2024 due to escalating demand in emergency and surgical transfusions. The platelets segment’s rapid expansion is underpinned by their pivotal role in treating patients with thrombocytopenia and cancer-related complications, as outlined in a 2025 clinical supply report. Whole blood remains essential but is seeing a relative decline in favor of component therapy, reflecting evolving market trends towards targeted, cost-efficient blood use.
Consumer Behaviour Insights
Recent market insights reveal notable shifts in consumer behavior within blood services. First, there is heightened pricing sensitivity among healthcare providers seeking cost-effective component therapies without compromising quality, as noted in a 2025 global hospital survey. Second, customization trends have emerged, with increased demand for patient-matched blood components using genetic typing technologies. Third, sustainability preferences influence procurement decisions, encouraging investments in eco-friendly blood storage and transportation solutions, supported by feedback from blood banks in 2024.
Key Players
Prominent Blood and Blood Components market players include Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, and Beckman Coulter. In 2024-2025, these market companies undertook multiple growth initiatives such as capacity expansions, enhanced product portfolios including pathogen reduction technologies, and regional network expansions, driving significant increases in market share and revenue streams.
Key Winning Strategies Adopted by Key Players
A standout strategy was implemented by Cerus Corporation in 2025, which involved commercialization of its INTERCEPT Blood System to effectively inactivate pathogens in platelets and plasma, reducing transfusion-transmitted infections and increasing market acceptance. Another innovative strategy was Becton, Dickinson & Co.'s integration of automated blood collection and testing platforms in 2024, resulting in a 15% improvement in operational efficiency for large hospital networks. Furthermore, Immucor’s focus on advanced immunohematology diagnostic solutions from 2024 enhanced product differentiation and propelled business growth in emerging markets.
FAQs
1. Who are the dominant players in the Blood and Blood Components Market?
Dominant players include Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, and Beckman Coulter, known for their strong product portfolios and strategic expansions during 2024-2025.
2. What will be the size of the Blood and Blood Components Market in the coming years?
The market size is projected to reach USD 56,242.3 million by 2032, growing at a CAGR of 4.7% from 2025.
3. Which end-user industry has the largest growth opportunity?
Hospitals dominate the end-user segment with the greatest revenue contribution, but specialized blood banks are witnessing the fastest growth due to expanding transfusion requirements.
4. How will development trends evolve in the Blood and Blood Components Market over the next five years?
Trends will emphasize automation in blood processing, personalized blood therapies, sustainability in storage solutions, and increased regulatory support for voluntary donations.
5. What is the nature of the competitive landscape and challenges in the Blood and Blood Components Market?
The competitive landscape is marked by innovation-driven market players focusing on technology-led differentiation. Challenges include stringent regulatory compliance and the need for cost-effective blood component technologies.
6. What go-to-market strategies are commonly adopted in the Blood and Blood Components Market?
Key strategies include new product launches focused on pathogen reduction, capacity expansions to meet growing demand, and regional market penetrations through collaborations and acquisitions.
Get More Insights On: Blood And Blood Components market
Get this Report in Japanese Language: 血液-血液成分市場
Get this Report in Korean Language: 혈액 및 혈액 성분 시장
Read More Articles Related to this Industry: Recent Developments in the CRISPR Technology Industry
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment